News

Prostate Cancer Awareness: Insights from ZERO's Response

Prostate Cancer Awareness: Insights from ZERO's Response

ZERO's Reaction to Prostate Cancer Diagnosis of a Former Leader

We express our deep concern upon hearing about Former President Joe Biden's diagnosis of an aggressive form of prostate cancer. Our hearts go out to the Biden family during this challenging time as they navigate through this health crisis.

Reports indicate that President Biden has received a Gleason score of 9, highlighting the highly aggressive nature of his cancer. This score is crucial as it serves as a key indicator of prostate cancer's severity.

The Gleason score, used by medical professionals, evaluates how aggressive prostate cancer is based on the appearance of cells under a microscope. A score of 9 is notable for its severity, and it has been shared that the cancer has unfortunately spread to the bones.

Dr. Alicia Morgans, Medical Chair of ZERO's Board of Directors and a renowned Genitourinary Medical Oncologist, noted, "While this is not encouraging news, it’s important to acknowledge that Biden’s cancer appears to be hormone-sensitive, indicating potential responsiveness to standard androgen deprivation therapy (ADT). This treatment method reduces testosterone levels in the body, effectively starving the cancer cells of their essential fuel for survival." She emphasized that with the right treatment, many people are able to live for several years while continuing to engage in their everyday activities.

Prostate cancer stands as the second leading cause of cancer death among men, with alarming statistics indicating that every two minutes, a man in the United States receives a prostate cancer diagnosis. Additionally, a man loses his life to this disease every 15 minutes.

Courtney Bugler, President and CEO of ZERO Prostate Cancer, emphasized, "This situation serves as a stark reminder that prostate cancer can affect anyone, regardless of their background or status. It is a wake-up call for all men to discuss their prostate cancer risk with healthcare professionals. Early detection through a simple PSA blood test can significantly impact survival outcomes.”

For close to 30 years, ZERO has been a leader in the fight against prostate cancer, equipping patients and families with vital resources, services, and support. The organization played a pivotal role in initiatives aimed at enhancing awareness and treatment options for prostate cancer. Recently, ZERO has taken the lead in launching a comprehensive initiative targeting prostate cancer, aptly named Blitz The Barriers. This ambitious project aims to save 100,000 lives by the year 2035.

Bugler voiced her concern, stating, "Prostate cancer is a pressing issue that we cannot overlook. This year alone, over 300,000 men will receive a prostate cancer diagnosis, with more than 35,000 succumbing to the disease. With such high stakes, it is essential to dismantle the barriers surrounding early detection, treatment, and care that are so crucial for survival."

Men interested in learning more about the PSA screening test, as well as resources for early and advanced-stage diagnosis, can visit the ZERO Prostate Cancer website for further information and support.

Understanding ZERO Prostate Cancer

ZERO Prostate Cancer is dedicated to enhancing lives impacted by prostate cancer through advocacy, education, and support. Established in 1996, previously known as the National Prostate Cancer Coalition, ZERO has evolved into the leading voice in prostate cancer awareness and funding research for groundbreaking treatment solutions. Over the past three decades, the organization has been instrumental in providing comprehensive resources, supporting millions of individuals diagnosed with prostate cancer.

As the nation's primary provider for prostate cancer resources and initiatives, ZERO continues to work tirelessly to bridge gaps in diagnosis, treatment, and care, focusing on individuals most affected by this condition. To discover more, please visit ZEROcancer.org.

MEDIA CONTACT:
Steph Johnson
Vice President, Communications
ZERO Prostate Cancer
For inquiries, please contact ZERO Prostate Cancer.

Frequently Asked Questions

What is the Gleason score in prostate cancer?

The Gleason score measures the aggressiveness of prostate cancer based on the appearance of cells, with higher scores indicating more severe disease.

How can men detect prostate cancer early?

Early detection can be achieved through a simple PSA blood test, which helps assess prostate health and identify potential cancer risks.

What resources does ZERO Prostate Cancer offer?

ZERO provides various resources, programs, and support services aimed at individuals affected by prostate cancer and their families.

What is the goal of the Blitz The Barriers initiative?

Blitz The Barriers aims to save 100,000 lives by 2035 by improving early detection and treatment of prostate cancer.

How does prostate cancer typically affect men?

Prostate cancer can be life-altering, affecting a man's health and quality of life, but many can live well and maintain normal activities during treatment.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Hims & Hers Faces FTC Heat: Investor Class Action Looms

Updated Category News Views 61

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Continue Reading
TORRAS Cases Balance Protection with Slim Design for 2026

Updated Category News Views 144

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Continue Reading
Air Sealing First: Boosting Home Comfort & Efficiency

Updated Category News Views 69

Everyone wants a cozy, energy-efficient home, right? Well, the first step to achieving that might just surprise you. Forget about shoving more insulation into the walls for a second; air sealing should be your starting line. That's the drum Insulation Expert Mike Mancuso is beating, and he's got a point worth considering before you touch another insulation panel. Cracking...

Continue Reading
ST Engineering iDirect, MBSat Forge Middle East Satellite Hub

Updated Category News Views 181

Satellite Services Take Off in the Middle East Never thought the day would come where the Middle East is on the threshold of leapfrogging satellite tech, but here we are. ST Engineering iDirect just locked arms with MBSat—yep, that's part of the Mohammed Al Barwani Group—to birth a next-gen satellite connectivity service hub in Oman and across surrounding areas....

Continue Reading
Miranda Lambert Lights Up Red Kettle Campaign

Updated Category News Views 28

A Star-Studded Start to the Season of Giving Miranda Lambert is set to dazzle audiences yet again, and if there's one thing this country music titan knows, it's how to crank up the heartstrings while fanning the flames of generosity. She'll take to the stage at AT&T Stadium this Thanksgiving during the Dallas Cowboys game, bringing a powerful performance to light up the...

Continue Reading
Gildan Activewear Faces Legal Battle Over Alleged Fraud

Updated Category News Views 80

Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 149

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 252

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
Monster Energy Unleashes Gaming Frenzy at Cosm L.A. Event

Updated Category News Views 96

Where Energy Drinks and Digital Reality Collide Monster Energy sure knows how to throw a party, especially when it hinges on something as electrifying as Call of Duty: Modern Warfare 4. Imagine this: Cosm Los Angeles is decked out with a massive 87-foot LED dome, and every gamer, celeb, and influencer ready to dive right in. You can't make this stuff up. They've mashed...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 331

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading

Top 5 Most Recently Viewed Articles

Warner Bros. Discovery's Remarkable Stock Surge Explained

Updated Category News Views 309

Warner Bros. Discovery Experiences Impressive Stock Surge Warner Bros. Discovery Inc. (NASDAQ: WBD) has been making headlines recently, with its stock surging dramatically. Investors and market enthusiasts are keenly observing this upward trend, particularly following a substantial rally. Record-Breaking Rally The company achieved an incredible milestone with its largest...

Continue Reading
Stellantis Reports 20% Q3 Shipment Drop, Market Reactions

Updated Category News Views 98

Stellantis Faces Significant Q3 Shipment Decline Stellantis (EPA: STLAM) (NYSE: STLA) recently reported a 20% drop in global shipments for the third quarter, prompting a notable reaction in the markets. The decline has been attributed to several factors including strategic inventory reduction measures and delays in the release of new models. During this challenging...

Continue Reading
Stifel Affirms Buy Rating on Elanco Amid New Drug Approval

Updated Category News Views 70

Stifel Stands Firm on Elanco Animal Health Stifel, a prominent financial services firm, has recently reaffirmed its Buy rating for Elanco Animal Health (NYSE: ELAN) and has kept its price target at $20.00 per share. This decision comes on the heels of the U.S. Food and Drug Administration's (FDA) approval of Elanco's new drug, Zenrelia, which serves as a significant boost...

Continue Reading
ChargePoint and Siemens Drive EV Infrastructure Innovation

Updated Category News Views 94

ChargePoint and Siemens Lead the Charge in Clean Tech The clean tech revolution is moving at an impressive pace, particularly with the growth of electric vertical takeoff and landing (eVTOL) aircraft and electric vehicle (EV) infrastructure. Companies like ChargePoint Holdings Inc (NYSE: CHPT) and Siemens AG (OTCPK: SIEGY) are crucial in shaping a sustainable future for...

Continue Reading
Elevance Health Faces Class Action: Investors Seek Remedies

Updated Category News Views 259

Opportunities for Investors in Elevance Health Class Action The recent developments surrounding Elevance Health, Inc. have prompted considerable attention, particularly among investors who have experienced substantial financial losses. The law firm Robbins Geller Rudman & Dowd LLP has initiated a class action lawsuit targeting Elevance Health, which operates in the health...

Continue Reading